The first patient has been enrolled in the Adaptive ChemoTherapy for Ovarian cancer trial
In 2021, Barts Charity awarded Dr Michelle Lockley of Barts Cancer Institute, Queen Mary University of London, nearly £500,000 to investigate a new personalised treatment approach for ovarian cancer.